McKesson Corporation $MCK Stock: Plancorp LLC Boosts Holdings

Plancorp LLC lifted its position in shares of McKesson Corporation (NYSE:MCK) by 74.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,557 shares of the company’s stock after acquiring an additional 665 shares during the quarter. Plancorp LLC’s holdings in McKesson were worth $1,329,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Nvwm LLC increased its stake in McKesson by 933.3% in the 3rd quarter. Nvwm LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 28 shares in the last quarter. Delos Wealth Advisors LLC purchased a new stake in McKesson during the second quarter worth $27,000. Trellis Wealth Advisors LLC purchased a new stake in McKesson during the third quarter worth $32,000. Clearstead Trust LLC purchased a new stake in McKesson during the second quarter worth $37,000. Finally, GK Wealth Management LLC acquired a new stake in McKesson in the third quarter valued at $38,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

Insider Transactions at McKesson

In related news, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total transaction of $98,950.95. Following the transaction, the chief accounting officer owned 521 shares of the company’s stock, valued at approximately $464,445.45. This represents a 17.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Francisco Fraga sold 650 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $1,102.96, for a total transaction of $716,924.00. Following the sale, the executive vice president owned 4,414 shares in the company, valued at approximately $4,868,465.44. This trade represents a 12.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,462 shares of company stock worth $2,511,106 over the last ninety days. 0.06% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Evercore restated an “outperform” rating and issued a $950.00 price target (down from $1,000.00) on shares of McKesson in a research report on Thursday, August 6th. Bank of America boosted their price objective on shares of McKesson from $950.00 to $1,050.00 in a research report on Thursday, August 6th. Mizuho increased their price objective on shares of McKesson from $905.00 to $1,020.00 and gave the company a “neutral” rating in a research note on Tuesday, October 20th. Wells Fargo & Company raised their target price on shares of McKesson from $812.00 to $933.00 and gave the company an “equal weight” rating in a report on Tuesday, August 11th. Finally, Leerink Partners lifted their target price on shares of McKesson from $1,070.00 to $1,200.00 and gave the stock an “outperform” rating in a research report on Thursday. Fifteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,026.18.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

McKesson Stock Down 1.0%

Shares of NYSE:MCK opened at $1,060.79 on Friday. The company has a market capitalization of $122.48 billion, a P/E ratio of 27.28, a P/E/G ratio of 2.08 and a beta of 0.27. McKesson Corporation has a 52-week low of $723.68 and a 52-week high of $1,121.50. The stock’s fifty day simple moving average is $938.13 and its 200-day simple moving average is $868.12.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, topping analysts’ consensus estimates of $10.72 by $0.96. McKesson had a negative return on equity of 202.94% and a net margin of 1.12%. The firm had revenue of $110.96 billion during the quarter, compared to analysts’ expectations of $109.90 billion. During the same quarter last year, the business posted $9.86 EPS. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. On average, sell-side analysts anticipate that McKesson Corporation will post 46.21 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Tuesday, December 1st will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Tuesday, December 1st. McKesson’s dividend payout ratio (DPR) is currently 9.67%.

McKesson Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.